228 related articles for article (PubMed ID: 24699306)
1. Heparanase enhances myeloma progression via CXCL10 downregulation.
Barash U; Zohar Y; Wildbaum G; Beider K; Nagler A; Karin N; Ilan N; Vlodavsky I
Leukemia; 2014 Nov; 28(11):2178-87. PubMed ID: 24699306
[TBL] [Abstract][Full Text] [Related]
2. Heparanase promotes myeloma stemness and in vivo tumorigenesis.
Tripathi K; Ramani VC; Bandari SK; Amin R; Brown EE; Ritchie JP; Stewart MD; Sanderson RD
Matrix Biol; 2020 Jun; 88():53-68. PubMed ID: 31812535
[TBL] [Abstract][Full Text] [Related]
3. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.
Ramani VC; Yang Y; Ren Y; Nan L; Sanderson RD
J Biol Chem; 2011 Feb; 286(8):6490-9. PubMed ID: 21131364
[TBL] [Abstract][Full Text] [Related]
4. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function.
Amin R; Tripathi K; Sanderson RD
Cells; 2020 Sep; 9(9):. PubMed ID: 32899927
[TBL] [Abstract][Full Text] [Related]
7. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.
Ramani VC; Zhan F; He J; Barbieri P; Noseda A; Tricot G; Sanderson RD
Oncotarget; 2016 Jan; 7(2):1598-607. PubMed ID: 26624982
[TBL] [Abstract][Full Text] [Related]
8. Heparanase promotes glioma progression via enhancing CD24 expression.
Barash U; Spyrou A; Liu P; Vlodavsky E; Zhu C; Luo J; Su D; Ilan N; Forsberg-Nilsson K; Vlodavsky I; Yang X
Int J Cancer; 2019 Sep; 145(6):1596-1608. PubMed ID: 31032901
[TBL] [Abstract][Full Text] [Related]
9. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.
Purushothaman A; Chen L; Yang Y; Sanderson RD
J Biol Chem; 2008 Nov; 283(47):32628-36. PubMed ID: 18812315
[TBL] [Abstract][Full Text] [Related]
10. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
[TBL] [Abstract][Full Text] [Related]
11. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.
Barash U; Cohen-Kaplan V; Dowek I; Sanderson RD; Ilan N; Vlodavsky I
FEBS J; 2010 Oct; 277(19):3890-903. PubMed ID: 20840586
[TBL] [Abstract][Full Text] [Related]
12. Heparanase: A Dynamic Promoter of Myeloma Progression.
Purushothaman A; Sanderson RD
Adv Exp Med Biol; 2020; 1221():331-349. PubMed ID: 32274716
[TBL] [Abstract][Full Text] [Related]
13. Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
Yang Y; Macleod V; Bendre M; Huang Y; Theus AM; Miao HQ; Kussie P; Yaccoby S; Epstein J; Suva LJ; Kelly T; Sanderson RD
Blood; 2005 Feb; 105(3):1303-9. PubMed ID: 15471949
[TBL] [Abstract][Full Text] [Related]
14. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
15. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
16. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.
Suvannasankha A; Tompkins DR; Edwards DF; Petyaykina KV; Crean CD; Fournier PG; Parker JM; Sandusky GE; Ichikawa S; Imel EA; Chirgwin JM
Oncotarget; 2015 Aug; 6(23):19647-60. PubMed ID: 25944690
[TBL] [Abstract][Full Text] [Related]
17. Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.
Yang Y; Ren Y; Ramani VC; Nan L; Suva LJ; Sanderson RD
Cancer Res; 2010 Nov; 70(21):8329-38. PubMed ID: 20978204
[TBL] [Abstract][Full Text] [Related]
18. Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer.
Cohen-Kaplan V; Jrbashyan J; Yanir Y; Naroditsky I; Ben-Izhak O; Ilan N; Doweck I; Vlodavsky I
J Biol Chem; 2012 Feb; 287(9):6668-78. PubMed ID: 22194600
[TBL] [Abstract][Full Text] [Related]
19. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.
Barash U; Cohen-Kaplan V; Arvatz G; Gingis-Velitski S; Levy-Adam F; Nativ O; Shemesh R; Ayalon-Sofer M; Ilan N; Vlodavsky I
FASEB J; 2010 Apr; 24(4):1239-48. PubMed ID: 20007507
[TBL] [Abstract][Full Text] [Related]
20. Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.
Li J; Pan Q; Rowan PD; Trotter TN; Peker D; Regal KM; Javed A; Suva LJ; Yang Y
Oncotarget; 2016 Mar; 7(10):11299-309. PubMed ID: 26849235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
